Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the 'PIPE') for gross proceeds of $30 million, before deducting expenses.

Nektar Therapeutics（Nasdaq:NKTR）是一家开发用于治疗自身免疫性疾病的药物的生物技术公司，今天宣布，它已与机构认可投资者TCGX签订了证券购买协议，以私募融资（“PIPE”）的方式出售证券，总收益为3000万美元，扣除费用前。

In the PIPE, Nektar is selling 25 million shares of its common stock, in the form of a pre-funded warrant, at a price of $1.20 per share, representing a premium of approximately 80% to Nektar's 30-day volume-weighted average price. The pre-funded warrant will have an exercise price of $0.0001 per share and will not expire.

在管道中，Nektar以预先出资的认股权证的形式出售2500万股普通股，价格为每股1.20美元，比Nektar的30天成交量加权平均价格溢价约80%。预先出资的认股权证的行权价格为每股0.0001美元，不会到期。

The PIPE is expected to close on or before March 6, 2024, subject to customary closing conditions. Nektar has agreed to submit a registration statement filing for the underlying Common Stock no later than 90 days after the closing.

根据惯例关闭条件，管道预计将于2024年3月6日或之前关闭。Nektar已同意不迟于交割后90天提交标的普通股登记声明。

'We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata,' said Howard Robin, President and Chief Executive Officer of Nektar Therapeutics. 'We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar.

Nektar Therapeutics总裁兼首席执行官霍华德·罗宾（HowardRobin）说：“我们很高兴让TCGX成为Nektar的新的高质量长期投资者，因为我们通过特应性皮炎和斑秃的2b期研究推进了rezpegaldesleukin的发展。”我们将在2025年上半年报告这些研究的主要数据，这将是Nektar的重要转折点。

Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026.'

今天的融资进一步巩固了我们的财务状况，并将公司的现金跑道延长至2026年第三季度。”

Rezpegaldesleukin is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways.

Rezpegaldesleukin是一种新型激动性T调节细胞生物制剂，旨在通过直接扩增功能性T reg细胞和参与多种免疫调节途径来抑制炎症反应并同时恢复免疫平衡。

About Nektar Therapeutics

关于Nektar Therapeutics

Nektar Therapeutics is a biotechnology company with a wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional manufacturing operations in Huntsville, Alabama.

Nektar Therapeutics是一家生物技术公司，拥有免疫学和肿瘤学研究药物的全资研发渠道，以及经批准的合作药物组合。Nektar总部位于加利福尼亚州旧金山，在阿拉巴马州亨茨维尔设有额外的制造业务。